Repository navigation
v0.5.1 (Alpha)
SYNAPTIK v0.5.1: Translational Fluid Biomarker & Patient Stratification Panel
This release bridges in vitro disease model findings directly to clinical fluid biomarkers (Neurofilament Light Chain, NfL) and patient cohort stratification for clinical trial optimization.
Highlights
-
synaptik biomarkerCLI command & API:- Models longitudinal in vivo biomarker suppression (plasma and CSF NfL via Simoa ultrasensitive assay) from in vitro axonal rescue percentages.
- Implements clearance pharmacodynamics (
$t_{1/2} = 8\text{ weeks}$ , translation scaling factor$\beta = 0.72$ ), projecting suppression curves at Weeks 4, 8, 12, 16, 24, 36, and 48. - Benchmarked against clinical trial precedents: VALOR study (SOD1 tofersen, Miller et al. NEJM 2022: ~60% plasma NfL suppression; FDA Accelerated Approval surrogate endpoint framework).
-
Clinical trial patient stratification & cohort optimization:
- Classifies patients into progression tiers (fast, intermediate, slow) based on baseline plasma NfL cutoffs (
$> 75\text{ pg/mL}$ ,$40\text{--}75\text{ pg/mL}$ ,$< 40\text{ pg/mL}$ ). - Computes trial power and sample size requirements: demonstrates that biomarker-enriched patient stratification reduces required patient cohort size per arm by 60–75% (e.g. from 74 down to 18 patients/arm) to detect 30% therapeutic slowing of functional decline (ALSFRS-R).
- Classifies patients into progression tiers (fast, intermediate, slow) based on baseline plasma NfL cutoffs (
-
Test coverage:
- 21 new regression checks in
tests/test_biomarker.py, bringing the total platform test suite to 321 passing checks across Python 3.10, 3.11, and 3.12.
- 21 new regression checks in